Rankia USA Rankia Argentina Rankia Argentina Rankia Chile Rankia Chile Rankia Colombia Rankia Colombia Rankia España Rankia España Rankia México Rankia México Rankia Perú Rankia Perú Rankia Portugal Rankia Portugal
Acceder

Threshold Pharmaceuticals, Inc (THLD): Opiniones

12,3K respuestas
Threshold Pharmaceuticals, Inc (THLD): Opiniones
3
suscriptores
Threshold pharmaceuticals, inc (thld): opiniones
Página
1 / 1.539
#1

Threshold Pharmaceuticals, Inc (THLD): Opiniones

Enolagay
Rankiano desde hace casi 10 años
Publicaciones
Recomendaciones
Seguidores
Ir al perfil
Enolagay

Tanto por técnico como por fundamentales.

Muchas gracias a todo el que se anime a contestar.

1 recomendaciones
#2

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Enrique Valls
Rankiano desde hace más de 9 años
Publicaciones
Recomendaciones
Seguidores
Ir al perfil
Enrique Valls

Ratios financieros:

Noticias:
18 Nov 2010 08:25am EST

Threshold Pharmaceuticals, Inc. announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. Today's presentation focused on two clinical trials, the 402 trial and the 403 trial. The 402 trial is a Phase 1/2, three arm, multicenter, dose escalation and dose expansion trial to determine the safety, efficacy and pharmacokinetics of TH-302 in combination with gemcitabine (Gem) or docetaxel (Doc) or pemetrexed (Pem) in patients with various advanced solid tumors including, but not limited to, advanced or metastatic pancreatic cancer, castrate-resistant prostate cancer (CRPC) and relapsed or refractory non-small cell lung cancer (NSCLC). The 403 trial is investigating TH-302 in combination with doxorubicin (Dox) in patients with advanced soft tissue sarcoma. Additionally, in the gemcitabine treatment arm, median progression free survival (PFS) was 6.4 months (95% CI: 4.7 to 7.7 months). Among the patients with relapsed or refractory NSCLC, median PFS was 4.2 months (95% CI: 2.8 months to not reached). Among the 15 patients with CRPC, 11 (73%) had a PSA decline of at least 50%. Among the patients with soft tissue sarcoma, median PFS was 6.4 months (95% CI: 5.6 to 6.9 months). Overall, hematologic toxicity was acceptable and skin and mucosal toxicities were well managed at current dose levels.

Fuente: Reuters

Sigue tus inversiones con Mi Cartera

#5

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Enolagay
Rankiano desde hace casi 10 años
Publicaciones
Recomendaciones
Seguidores
Ir al perfil
Enolagay

Esta compañía no encajaría con Zeltia?
No sé , la voy a seguir...por si las moscas.

Brokers destacados